Identifying biomarkers to monitor Alzheimer's disease progression
Brain Connectivity and Complexity Parameters to Monitor Disease Progression in Dementia Patients and Antiinflammatory Nanotherapeutics in a Preclinical Model of Alzheimer's Disease
This study is trying to find early signs of Alzheimer's disease and understand how inflammation affects it, to help improve detection and treatment for people with mild Alzheimer's and mild cognitive impairment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Roma Academic / other |
| Locations | 2 sites (Roma and 1 other locations) |
| Trial ID | NCT06855368 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the neurophysiological parameters associated with mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) by comparing these patients to matched healthy subjects. The research focuses on understanding the deterioration of cortical connectivity networks as potential early markers of cognitive decline. Additionally, the study will investigate the role of neuroinflammation in AD progression using a mouse model, with the goal of developing innovative anti-inflammatory nanoparticles that can influence brain microglia. By identifying discriminating criteria, the study seeks to enhance early detection and intervention strategies for AD.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals diagnosed with mild Alzheimer's disease or mild cognitive impairment.
Not a fit: Patients with major psychosis, other neurological disorders, or conditions affecting cognitive status may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and monitoring of Alzheimer's disease, potentially allowing for timely interventions.
How similar studies have performed: While the approach of using neurophysiological parameters and biomarkers in Alzheimer's research is established, the specific combination of methods in this study is innovative and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * mild AD and patients with mild cognitive impairment (MCI). Exclusion Criteria: * major psychosis, genetic, metabolic and other neurological disorders, acute or chronic non-compensated medical illness * any medical or drug-related condition affecting cognitive or mood status * history or current alcohol/illicit drug abuse.
Where this trial is running
Roma and 1 other locations
- IRCCS San Raffaele — Roma, Italy (Active_not_recruiting)
- Azienda Ospedaliero-Universitaria di Sassari — Sassari, Italy (Recruiting)
Study contacts
- Study coordinator: Lucia Gatta, PhD
- Email: lucia.gatta@sanraffaele.it
- Phone: +390652253440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.